Jpmorgan Chase & CO Immuno Gen, Inc. Transaction History

Jpmorgan Chase & CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$12.46 - $29.95 $1.68 Million - $4.05 Million	-135,173 Reduced 6.15%	2,063,254 $61.2 Million
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $18.8 Million - $26.5 Million	1,336,005 Added 154.91%	2,198,427 $34.9 Million
Q2 2023 Aug 11, 2023	SELL	$3.75 - $20.05 $398,666 - $2.13 Million	-106,311 Reduced 10.97%	862,422 $16.3 Million
Q1 2023 May 18, 2023	BUY	$3.67 - $4.92 $960,725 - $1.29 Million	261,778 Added 37.03%	968,733 $3.72 Million
Q1 2023 May 11, 2023	BUY	$3.67 - $4.92 $1.8 Million - $2.41 Million	490,488 Added 226.59%	706,955 $2.71 Million
Q4 2022 Feb 13, 2023	BUY	$4.55 - $6.31 $377,481 - $523,496	82,963 Added 62.14%	216,467 $1.07 Million
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $33,384 - $48,214	7,452 Added 5.91%	133,504 $638,000
Q2 2022 Aug 11, 2022	BUY	$3.15 - $5.76 $1,508 - $2,759	479 Added 0.38%	126,052 $568,000
Q1 2022 May 11, 2022	BUY	$4.26 - $7.48 $128,277 - $225,237	30,112 Added 31.54%	125,573 $598,000
Q4 2021 Feb 10, 2022	BUY	$4.75 - $7.5 $34,157 - $53,932	7,191 Added 8.15%	95,461 $709,000
Q3 2021 Nov 12, 2021	BUY	$5.02 - $6.59 $443,115 - $581,699	88,270 New	88,270 $500,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.